Crinetics Pharmaceuticals, Inc. CRNX
We take great care to ensure that the data presented and summarized in this overview for Crinetics Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CRNX
View all-
Vanguard Group Inc Valley Forge, PA9.26MShares$392 Million0.0% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.4MShares$271 Million1.78% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$264 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA5.81MShares$246 Million0.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.59MShares$237 Million0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA4.65MShares$197 Million0.6% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.29MShares$181 Million10.63% of portfolio
-
Janus Henderson Group PLC London, X03.41MShares$144 Million0.05% of portfolio
-
State Street Corp Boston, MA3.22MShares$136 Million0.0% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.34MShares$99.2 Million3.15% of portfolio
Latest Institutional Activity in CRNX
Top Purchases
Top Sells
About CRNX
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Insider Transactions at CRNX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 01
2025
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
5,000
-7.02%
|
$205,000
$41.81 P/Share
|
|
Oct 01
2025
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+6.56%
|
$80,000
$16.89 P/Share
|
|
Sep 26
2025
|
Matthew K Fust Director |
SELL
Open market or private sale
|
Direct |
16,000
-41.2%
|
$704,000
$44.75 P/Share
|
|
Sep 26
2025
|
Matthew K Fust Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+20.48%
|
$10,000
$1.91 P/Share
|
|
Sep 26
2025
|
Richard Scott Struthers President & CEO |
SELL
Open market or private sale
|
Indirect |
4,000
-3.64%
|
$180,000
$45.0 P/Share
|
|
Sep 02
2025
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
5,000
-4.94%
|
$160,000
$32.1 P/Share
|
|
Sep 02
2025
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.71%
|
$80,000
$16.89 P/Share
|
|
Aug 22
2025
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
30,000
-31.16%
|
$900,000
$30.43 P/Share
|
|
Aug 22
2025
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+23.76%
|
$480,000
$16.89 P/Share
|
|
Aug 20
2025
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
6,492
-8.92%
|
$188,268
$29.18 P/Share
|
|
Jun 12
2025
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
97,483
-49.43%
|
$3,119,456
$32.23 P/Share
|
|
Jun 12
2025
|
Stephen F. Betz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
88,170
+18.08%
|
$440,850
$5.6 P/Share
|
|
Jun 11
2025
|
Wendall Wierenga |
BUY
Grant, award, or other acquisition
|
Direct |
6,900
+5.61%
|
-
|
|
Jun 11
2025
|
Weston Nichols |
BUY
Grant, award, or other acquisition
|
Direct |
6,900
+29.74%
|
-
|
|
Jun 11
2025
|
Camille L Bedrosian |
BUY
Grant, award, or other acquisition
|
Direct |
6,900
+29.74%
|
-
|
|
Jun 11
2025
|
Matthew K Fust Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,900
+19.31%
|
-
|
|
Jun 11
2025
|
Coelho Rogerio Vivaldi |
BUY
Grant, award, or other acquisition
|
Direct |
6,900
+24.47%
|
-
|
|
Jun 11
2025
|
Stephanie Okey |
BUY
Grant, award, or other acquisition
|
Direct |
6,900
+29.74%
|
-
|
|
Jun 11
2025
|
Caren Deardorf |
BUY
Grant, award, or other acquisition
|
Direct |
6,900
+29.74%
|
-
|
|
May 14
2025
|
Richard Scott Struthers President & CEO |
BUY
Bona fide gift
|
Indirect |
90,400
+12.03%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 318K shares |
|---|---|
| Exercise of conversion of derivative security | 244K shares |
| Bona fide gift | 90.4K shares |
| Open market or private sale | 227K shares |
|---|---|
| Bona fide gift | 90.4K shares |